drugset
drugset / Trial / NCT05955027

A Study to Evaluate the Effect of a Single Oral Dose of ZX-7101A on the QTc Interval in Healthy Subjects

NCT05955027 ↗

Phase 1 Completed 24 enrolled Nanjing Zenshine Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the effect of a single oral dose of ZX-7101A on the QTc interval in healthy subjects.

Timeline

Start
2023-07-08
Primary completion
2023-08-05
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ZX-7101A Unknown 80 mg Oral
Subject ZX-7101A Unknown 160 mg Oral

Indications

influenza